Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.

Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG 3rd.

Biol Blood Marrow Transplant. 2019 Nov 27. pii: S1083-8791(19)30830-4. doi: 10.1016/j.bbmt.2019.11.024. [Epub ahead of print]

PMID:
31785375
2.

DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.

Choudhry P, Mariano MC, Geng H, Martin TG 3rd, Wolf JL, Wong SW, Shah N, Wiita AP.

Leukemia. 2019 Oct 8. doi: 10.1038/s41375-019-0587-5. [Epub ahead of print] No abstract available.

PMID:
31595037
3.

Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.

Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L, Kamperschroer C, Pascua E, Chen W, Delaria K, Farias S, Bateman M, Dushin RG, Chin SM, Van Blarcom TJ, Yeung YA, Lindquist KC, Chunyk AG, Kuang B, Han B, Mirsky M, Pardo I, Buetow B, Martin TG, Wolf JL, Shelton D, Rajpal A, Strop P, Chaparro-Riggers J, Sasu BJ.

Mol Cancer Ther. 2019 Nov;18(11):2008-2020. doi: 10.1158/1535-7163.MCT-19-0007. Epub 2019 Aug 21.

PMID:
31434693
4.

Safety of Endoscopy in Heritable Connective Tissue Disorders.

Kilaru SM, Mukamal KJ, Nee JW, Oza SS, Lembo AJ, Wolf JL.

Am J Gastroenterol. 2019 Aug;114(8):1343-1345. doi: 10.14309/ajg.0000000000000189.

PMID:
31185005
5.

Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies.

LeBlanc TW, Baile WF, Eggly S, Bylund CL, Kurtin S, Khurana M, Najdi R, Blaedel J, Wolf JL, Fonseca R.

Patient Educ Couns. 2019 Sep;102(9):1602-1612. doi: 10.1016/j.pec.2019.04.028. Epub 2019 Apr 26. Review.

PMID:
31076236
6.

Sclerosing Mesenteritis.

Danford CJ, Lin SC, Wolf JL.

Am J Gastroenterol. 2019 Jun;114(6):867-873. doi: 10.14309/ajg.0000000000000167.

PMID:
30829677
7.

Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.

Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1218-1224. doi: 10.1016/j.bbmt.2019.01.028. Epub 2019 Jan 30.

PMID:
30708189
8.

Fatal Umbilical Cord Strangulation in the Remaining Co-Twin after Selective Foeticide with Radiofrequency Ablation for Twin-Twin Transfusion Syndrome.

Tollenaar LSA, Knijnenburg PCJ, Wolf JL, Slaghekke F, Middeldorp JM, Haak MC, Klumper FJC, Oepkes D, Lopriore E.

Fetal Diagn Ther. 2019;45(6):441-444. doi: 10.1159/000493790. Epub 2018 Nov 12.

9.

Encapsulating peritoneal sclerosis.

Danford CJ, Lin SC, Smith MP, Wolf JL.

World J Gastroenterol. 2018 Jul 28;24(28):3101-3111. doi: 10.3748/wjg.v24.i28.3101. Review.

10.

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.

Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG 3rd, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M.

Mol Cancer Ther. 2017 Nov;16(11):2375-2386. doi: 10.1158/1535-7163.MCT-17-0233. Epub 2017 Sep 6.

11.

Response to Morton.

Liu J, Ghaziani TT, Wolf JL.

Am J Gastroenterol. 2017 Aug;112(8):1342-1343. doi: 10.1038/ajg.2017.186. No abstract available.

PMID:
28766578
12.

Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports.

Le TX, Wolf JL, Peralta CA, Webber AB.

Am J Kidney Dis. 2017 Jun;69(6):858-862. doi: 10.1053/j.ajkd.2016.12.023. Epub 2017 Mar 18.

PMID:
28320553
13.

Acute Fatty Liver Disease of Pregnancy: Updates in Pathogenesis, Diagnosis, and Management.

Liu J, Ghaziani TT, Wolf JL.

Am J Gastroenterol. 2017 Jun;112(6):838-846. doi: 10.1038/ajg.2017.54. Epub 2017 Mar 14. Review.

PMID:
28291236
14.

Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.

Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B.

J Clin Invest. 2016 Dec 1;126(12):4640-4653. doi: 10.1172/JCI85856. Epub 2016 Nov 14.

15.

The past, the present, and the future in the gastrointestinal health of women: An interview with Dr Jacqueline L Wolf.

Wolf JL.

Womens Health (Lond). 2016 Jul;12(4):393-5. doi: 10.1177/1745505716655556. No abstract available.

16.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1609-1618. Epub 2016 Sep 1.

17.

Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study.

Zenlea T, Yee EU, Rosenberg L, Boyle M, Nanda KS, Wolf JL, Falchuk KR, Cheifetz AS, Goldsmith JD, Moss AC.

Am J Gastroenterol. 2016 May;111(5):685-90. doi: 10.1038/ajg.2016.50. Epub 2016 Mar 15.

PMID:
26977756
18.

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.

Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S.

Blood. 2016 May 26;127(21):2561-8. doi: 10.1182/blood-2015-11-682518. Epub 2016 Mar 1.

PMID:
26932802
19.

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.

Mannis GN, Martin TG 3rd, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1030-1036. doi: 10.1016/j.bbmt.2016.02.004. Epub 2016 Feb 16.

20.

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.

Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL.

Am J Hematol. 2016 Jun;91(4):400-5. doi: 10.1002/ajh.24300.

21.

Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.

Mannis GN, Martin TG 3rd, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C.

Leuk Lymphoma. 2016 Jul;57(7):1560-6. doi: 10.3109/10428194.2015.1088646. Epub 2016 Jan 4.

PMID:
26490487
22.

A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.

Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG 3rd.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):377-83. doi: 10.1016/j.clml.2015.02.016. Epub 2015 Feb 14.

PMID:
25776193
23.

Complementary and Alternative Medicine Use Is Prevalent Among Patients with Gastrointestinal Diseases.

Hung A, Kang N, Bollom A, Wolf JL, Lembo A.

Dig Dis Sci. 2015 Jul;60(7):1883-8. doi: 10.1007/s10620-014-3498-3. Epub 2015 Jan 4. Review.

PMID:
25556585
24.

The development of potential antibody-based therapies for myeloma.

Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B.

Blood Rev. 2015 Mar;29(2):81-91. doi: 10.1016/j.blre.2014.09.011. Epub 2014 Sep 28. Review.

25.

Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.

Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG.

Bone Marrow Transplant. 2015 Jan;50(1):40-4. doi: 10.1038/bmt.2014.201. Epub 2014 Sep 22.

PMID:
25243620
26.

Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.

Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL.

J Geriatr Oncol. 2014 Jul;5(3):238-44. doi: 10.1016/j.jgo.2014.04.003. Epub 2014 Jun 2.

PMID:
24894413
27.

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.

Hamilton M, Wolf JL, Drolet DW, Fettner SH, Rakhit AK, Witt K, Lum BL.

Cancer Chemother Pharmacol. 2014 Mar;73(3):613-21. doi: 10.1007/s00280-014-2390-3. Epub 2014 Jan 29.

PMID:
24474302
28.

Infrared detection of Criegee intermediates formed during the ozonolysis of β-pinene and their reactivity towards sulfur dioxide.

Ahrens J, Carlsson PT, Hertl N, Olzmann M, Pfeifle M, Wolf JL, Zeuch T.

Angew Chem Int Ed Engl. 2014 Jan 13;53(3):715-9. doi: 10.1002/anie.201307327.

PMID:
24402798
29.

Complementary and alternative medicine and mind-body therapies for treatment of irritable bowel syndrome in women.

Magge SS, Wolf JL.

Womens Health (Lond). 2013 Nov;9(6):557-67. doi: 10.2217/whe.13.57. Review.

PMID:
24161308
30.

Management of fertility and pregnancy in women with inflammatory bowel disease: a practical guide.

Friedman S, McElrath TF, Wolf JL.

Inflamm Bowel Dis. 2013 Dec;19(13):2937-48. doi: 10.1097/MIB.0b013e3182a0ea6f. Review. No abstract available.

PMID:
23945187
31.

Histologic markers of inflammation in patients with ulcerative colitis in clinical remission.

Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, Wolf JL, Cheifetz AS, Goldsmith JD, Moss AC.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):991-6. doi: 10.1016/j.cgh.2013.02.030. Epub 2013 Apr 13.

32.

Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission.

Rosenberg L, Lawlor GO, Zenlea T, Goldsmith JD, Gifford A, Falchuk KR, Wolf JL, Cheifetz AS, Robson SC, Moss AC.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):779-84. doi: 10.1097/MIB.0b013e3182802b0e.

33.

Successful Treatment with Methylnaltrexone and IVIG for Paraneoplastic Syndrome-Associated Intestinal Pseudo-Obstruction.

Zhang C, Patel NJ, Jacobs WC, Ullman S, Berzin TM, Chuttani R, Lembo AJ, Wolf JL.

Gastroenterol Hepatol (N Y). 2013 Jan;9(1):48-51. No abstract available.

34.

Pressure dependent aerosol formation from the cyclohexene gas-phase ozonolysis in the presence and absence of sulfur dioxide: a new perspective on the stabilisation of the initial clusters.

Carlsson PT, Dege JE, Keunecke C, Krüger BC, Wolf JL, Zeuch T.

Phys Chem Chem Phys. 2012 Sep 7;14(33):11695-705. doi: 10.1039/c2cp40714k. Epub 2012 Jul 24.

PMID:
22825796
35.

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.

Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S.

Leuk Lymphoma. 2012 Sep;53(9):1820-3. doi: 10.3109/10428194.2012.661175. Epub 2012 Mar 1. No abstract available.

PMID:
22288662
36.

Legal considerations for protecting the physician's assets.

Wolf JL.

J Med Pract Manage. 2011 Mar-Apr;26(5):310-3.

PMID:
21595387
37.

Pressure dependent mechanistic branching in the formation pathways of secondary organic aerosol from cyclic-alkene gas-phase ozonolysis.

Wolf JL, Richters S, Pecher J, Zeuch T.

Phys Chem Chem Phys. 2011 Jun 21;13(23):10952-64. doi: 10.1039/c0cp02499f. Epub 2011 Mar 25.

PMID:
21442094
38.

Colorectal cancer screening and prevention in women.

Krishnan S, Wolf JL.

Womens Health (Lond). 2011 Mar;7(2):213-26. doi: 10.2217/whe.11.7. Review.

PMID:
21410347
39.

Trends in intake and outcome data for animal shelters in Colorado, 2000 to 2007.

Morris KN, Wolf JL, Gies DL.

J Am Vet Med Assoc. 2011 Feb 1;238(3):329-36. doi: 10.2460/javma.238.3.329.

PMID:
21281216
40.

[Colorectal cancer in women: screening and prevention in 2011].

Krishnan S, Wolf JL.

Eksp Klin Gastroenterol. 2011;(11):97-101. Review. Russian. No abstract available.

PMID:
22629728
41.

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC.

Br J Haematol. 2010 Aug;150(4):428-37. doi: 10.1111/j.1365-2141.2010.08264.x. Epub 2010 Jul 7.

42.

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.

Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV.

Leukemia. 2010 Jul;24(7):1350-6. doi: 10.1038/leu.2010.116. Epub 2010 May 27.

43.

Effective interventions for homeless youth: a systematic review.

Altena AM, Brilleslijper-Kater SN, Wolf JL.

Am J Prev Med. 2010 Jun;38(6):637-45. doi: 10.1016/j.amepre.2010.02.017. Review.

PMID:
20494240
44.

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.

Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC Jr.

J Hematol Oncol. 2010 Mar 11;3:9. doi: 10.1186/1756-8722-3-9.

45.

Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.

Jagannath S, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A, Crowley J, Vescio R.

Br J Haematol. 2009 Sep;146(6):619-26. doi: 10.1111/j.1365-2141.2009.07803.x. Epub 2009 Jul 20.

PMID:
19622094
46.

Suppressed particle formation by kinetically controlled ozone removal: revealing the role of transient-species chemistry during alkene ozonolysis.

Wolf JL, Suhm MA, Zeuch T.

Angew Chem Int Ed Engl. 2009;48(12):2231-5. doi: 10.1002/anie.200805189.

PMID:
19206127
47.

Uniquely women's issues in colorectal cancer screening.

Wolf JL.

Am J Gastroenterol. 2006 Dec;101(12 Suppl):S625-9. Review.

PMID:
17177866
48.

Therapy insight: drugs for gastrointestinal disorders in pregnant women.

Thukral C, Wolf JL.

Nat Clin Pract Gastroenterol Hepatol. 2006 May;3(5):256-66. Review.

PMID:
16673005
49.

Effects of smoking on the pharmacokinetics of erlotinib.

Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71.

50.

Unmasking the impact of gender on inflammatory bowel disease.

Wolf JL.

Womens Health (Lond). 2005 Nov;1(3):299-303. doi: 10.2217/17455057.1.3.299. No abstract available.

PMID:
19803871

Supplemental Content

Support Center